



Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com

November 18, 2024

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – clarification on reported news article published in "<https://economictimes.indiatimes.com>" dated November 17, 2024

This is with reference to your e-mail dated November 18, 2024 and in relation to a news article which appeared in the "Website-www.economictimes.com" dated November 17, 2024 captioned "Dr Reddy's, FDC recall products in US for manufacturing issues"

In this connection, we wish to inform that on October 22, 2024, the Company initiated a voluntary retail-level recall of two (2) Lots of Morphine Sulfate Extended-Release Tablets 15mg and 30mg in the U.S. This recall was voluntarily undertaken by the Company out of an abundance of caution. The Company does not believe this development is material as defined under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please note that the above mentioned event/information was not considered as material requiring disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'). We further inform that there is no material impact of the above reported news on the Company.

In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations.

This is for your information and records.

Thanking you.

Yours faithfully,
For **Dr. Reddy's Laboratories Limited**

K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR